Snipr Biome takes aim at antibiotic resistant bacteria in phase I trial

Danish biotech company Snipr Biome, which is developing a new type of antibiotics using the gene-editing tool CRISPR, is sending its first candidate to clinic. ”It’s a huge day for us,” says CEO Christian Grøndahl.

Photo: Wolfgang Kumm/AP/Ritzau Scanpix

Danish biotech firm Snipr Biome announced on Wednesday that the first dose had been administered in a phase I trial with a potentially preventive treatment against E.coli infections in the gut.

”It’s a huge day for us. This is seven years of work culminating in us reaching the clinic. The most distinguished role of biotech is to bring new innovation into clinical studies to investigate whether it works, and this is what we’re doing,” says Christian Grøndahl, CEO and co-founder of Snipr Biome, which is expecting the first data to come in toward the end of the year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs